Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Ko, Sung Jun ^a   Lee, Yeon J ^a   Park, Jong S ^a   Cho, Young Jae ^a   Yoon, Ho I ^a   Chung, Jin Haeng ^b   Kim, Tae J ^a   Lee, Kyung W ^a   Kim, Kwhanmien ^a   Jheon, Sanghoon ^a   Kim, Hyojin ^c   Lee, Jae H ^a   Lee, Choon Taek ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Adenocarcinoma; ALK; EGFR; Lung cancer; nGGO

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE;

ADULT; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; TUMOR VOLUME; ADENOCARCINOMA; AGED; COMPUTER ASSISTED TOMOGRAPHY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RADIOGRAPHY;

ADENOCARCINOMA; AGED; FEMALE; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TOMOGRAPHY, X-RAY COMPUTED; TUMOR BURDEN;

EID: 84900541593     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-312     Document Type: Article

References (52)

1. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks J. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365(5):395-409.
2. Godoy MC, Naidich DP. Subsolid Pulmonary Nodules and the Spectrum of Peripheral Adenocarcinomas of the Lung: Recommended Interim Guidelines for Assessment and Management. Radiology 2009, 253(3):606-622. 10.1148/radiol.2533090179, 19952025.
3. Lee HY, Lee KS. Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications. J Thorac Imaging 2011, 26(2):106-118. 10.1097/RTI.0b013e3181fbaa64, 21508733.
4. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6(2):244-285. 10.1097/JTO.0b013e318206a221, 21252716.
5. Takeuchi T, Tomida S, Yatabe Y, Kosaka T, Osada H, Yanagisawa K, Mitsudomi T, Takahashi T. Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. J Thorac Oncol 2006, 24(11):1679-1688.
6. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010, 362(25):2380-2388. 10.1056/NEJMoa0909530, 20573926.
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010, 11(2):121-128. 10.1016/S1470-2045(09)70364-X, 20022809.
8. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011, 12(8):735-742. 10.1016/S1470-2045(11)70184-X, 21783417.
9. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S-I, Watanabe H, Kurashina K, Hatanaka H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566. 10.1038/nature05945, 17625570.
10. Kwak EL, Bang Y-J, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou S-HI, Dezube BJ, Jänne PA, Costa DB. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703. 10.1056/NEJMoa1006448, 3014291, 20979469.
11. Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, De Pas T, Besse B, Solomon BJ, Blackhall F. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394. 10.1056/NEJMoa1214886, 23724913.
12. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AKP, Govindan R. Non-Small Cell Lung Cancer. J Natl Compr Cancer Netw 2012, 10(10):1236-1271.
13. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar J-S, Squire J. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn 2013, 15(4):415-453. 10.1016/j.jmoldx.2013.03.001, 23562183.
14. Aoki T, Hanamiya M, Uramoto H, Hisaoka M, Yamashita Y, Korogi Y. Adenocarcinomas with Predominant Ground-Glass Opacity: Correlation of Morphology and Molecular Biomarkers. Radiology 2012, 264(2):590-596. 10.1148/radiol.12111337, 22653188.
15. Chung J-H, Choe G, Jheon S, Sung S-W, Kim TJ, Lee KW, Lee JH, Lee C-T. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol 2009, 4(12):1490-1495. 10.1097/JTO.0b013e3181bc9731, 19844187.
16. Yoshida Y, Kokubu A, Suzuki K, Kuribayashi H, Tsuta K, Matsuno Y, Kusumoto M, Kanai Y, Asamura H, Hirohashi S. Molecular markers and changes of computed tomography appearance in lung adenocarcinoma with ground-glass opacity. Jpn J Clin Oncol 2007, 37(12):907-912. 10.1093/jjco/hym139, 18089646.
17. Yano M, Sasaki H, Kobayashi Y, Yukiue H, Haneda H, Suzuki E, Endo K, Kawano O, Hara M, Fujii Y. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma. J Thorac Oncol 2006, 1(5):413-416. 10.1097/01243894-200606000-00006, 17409892.
18. Okada M, Nishio W, Sakamoto T, Uchino K, Tsubota N. Discrepancy of computed tomographic image between lung and mediastinal windows as a prognostic implication in small lung adenocarcinoma. Ann Thorac Surg 2003, 76(6):1828-1832. 10.1016/S0003-4975(03)01077-4, 14667592.
19. Goldstraw P. The 7th Edition of TNM in Lung Cancer: what now?. J Thorac Oncol 2009, 4(6):671-673. 10.1097/JTO.0b013e31819e7814, 19461399.
20. Kim HJ, Lee KY, Kim Y-C, Kim K-S, Lee SY, Jang TW, Lee MK, Shin K-C, Lee GH, Lee JC. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012, 75(3):321-325. 10.1016/j.lungcan.2011.08.005, 21930325.
21. Lee HJ, Xu X, Kim H, Jin Y, Sun P, Kim JE, Chung J-H. Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor. Korean J Pathol 2013, 47(1):52-60. 10.4132/KoreanJPathol.2013.47.1.52, 3589609, 23483646.
22. Paik JH, Choe G, Kim H, Choe J-Y, Lee HJ, Lee C-T, Lee JS, Jheon S, Chung J-H. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization. J Thorac Oncol 2011, 6(3):466-472. 10.1097/JTO.0b013e31820b82e8, 21258247.
23. Paik JH, Choi C-M, Kim H, Jang SJ, Choe G, Kim DK, Kim HJ, Yoon H, Lee C-T, Jheon S. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012, 76(3):403-409. 10.1016/j.lungcan.2011.11.008, 22129856.
24. Kim H, Shim HS, Kim L, Kim T-J, Kwon KY, Lee GK, Chung J-H. Guideline Recommendations for Testing of ALK Gene Rearrangement in Lung Cancer: a Proposal of the Korean Cardiopulmonary Pathology Study Group. Korean J Pathol 2014, 48:1-9. 10.4132/KoreanJPathol.2014.48.1.1, 3950228, 24627688.
25. Choi H, Paeng JC, Kim D-W, Lee JK, Park CM, Kang KW, Chung J-K, Lee DS. Metabolic and metastatic characteristics of ALK-rearranged lung adenocarcinoma on FDG PET/CT. Lung Cancer 2013, 79(3):242-247. 10.1016/j.lungcan.2012.11.021, 23261227.
26. Koh Y, Kim D-W, Kim TM, Lee S-H, Jeon YK, Chung DH, Kim Y-W, Heo DS, Kim W-H, Bang Y-J. Clinicopathologic characteristics and outcomes of patients with anaplastic lymphoma kinase-positive advanced pulmonary adenocarcinoma: suggestion for an effective screening strategy for these tumors. J Thorac Oncol 2011, 6(5):905-912. 10.1097/JTO.0b013e3182111461, 21358343.
27. Aoki T, Tomoda Y, Watanabe H, Nakata H, Kasai T, Hashimoto H, Kodate M, Osaki T, Yasumoto K. Peripheral Lung Adenocarcinoma: Correlation of Thin-Section CT Findings with Histologic Prognostic Factors and Survival. Radiology 2001, 220(3):803-809. 10.1148/radiol.2203001701, 11526285.
28. Takashima S, Maruyama Y, Hasegawa M, Yamanda T, Honda T, Kadoya M, Sone S. CT findings and progression of small peripheral lung neoplasms having a replacement growth pattern. Am J Roentgenol 2003, 180(3):817-826.
29. Fukui T, Yatabe Y, Kobayashi Y, Tomizawa K, Ito S, Hatooka S, Matsuo K, Mitsudomi T. Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. Lung Cancer 2012, 77(2):319-325. 10.1016/j.lungcan.2012.03.013, 22483782.
30. Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, Stubbs H, Law K, Lindeman N, Mark E. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009, 15(16):5216-5223. 10.1158/1078-0432.CCR-09-0802, 2865649, 19671850.
31. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012, 18(3):378-381. 10.1038/nm.2658, 22327623.
32. Wang Z, Zhang X, Bai H, Zhao J, Zhuo M, An T, Duan J, Yang L, Wu M, Wang S. EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. Oncology 2012, 83(5):248-256. 10.1159/000341381, 22964709.
33. Pillai RN, Ramalingam SS. The Biology and Clinical Features of Non-small Cell Lung Cancers with EML4-ALK Translocation. Curr Oncol Rep 2012, 14(2):105-110. 10.1007/s11912-012-0213-4, 22311682.
34. Jokoji R, Yamasaki T, Minami S, Komuta K, Sakamaki Y, Takeuchi K, Tsujimoto M. Combination of morphological feature analysis and immunohistochemistry is useful for screening of EML4-ALK-positive lung adenocarcinoma. J Clin Pathol 2010, 63(12):1066-1070. 10.1136/jcp.2010.081166, 20935334.
35. Yoshida A, Tsuta K, Nakamura H, Kohno T, Takahashi F, Asamura H, Sekine I, Fukayama M, Shibata T, Furuta K. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011, 35(8):1226-1234. 10.1097/PAS.0b013e3182233e06, 21753699.
36. Park J, Yamaura H, Yatabe Y, Hosoda W, Kondo C, Shimizu J, Horio Y, Yoshida K, Tanaka K, Oguri T, Kobayashi Y, Hida H. Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy. Cancer Med 2014, 3(1):118-123. 10.1002/cam4.172, 3930396, 24403104.
37. Yatabe Y, Kosaka T, Takahashi T, Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005, 29(5):633-639. 10.1097/01.pas.0000157935.28066.35, 15832087.
38. Park WY, Kim MH, Shin DH, Lee JH, Choi KU, Kim JY, Park DY, Lee CH, Sol MY. Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit origin. Mod Pathol 2012, 25(9):1265-1274. 10.1038/modpathol.2012.76, 22555174.
39. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, Mun M-Y, Sakao Y, Okumura S, Nakagawa K. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009, 22(4):508-515. 10.1038/modpathol.2009.2, 19234440.
40. Li Y, Li Y, Yang T, Wei S, Wang J, Wang M, Wang Y, Zhou Q, Liu H, Chen J. Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer. PLoS One 2013, 8(1):e52093. 10.1371/journal.pone.0052093, 3544857, 23341890.
41. Takahashi T, Kobayashi M, Yoshizawa A, Menju T, Nakayama E. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol 2010, 17(3):889-897. 10.1245/s10434-009-0808-7, 20183914.
42. Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, Nam KH, Paik JH, Chung JH. A comprehensive comparative analysis of the histomorphological features of ALK-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial-mesenchymal transition markers than other genotype. PLoS One 2013, 8(10):e76999. 10.1371/journal.pone.0076999, 3806726, 24194854.
43. Kang HJ, Lim HJ, Park JS, Cho YJ, Yoon HI, Chung JH, Lee JH, Lee CT. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med 2014, 108(2):388-394. 10.1016/j.rmed.2013.11.020, 24361161.
44. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350(21):2129-2139. 10.1056/NEJMoa040938, 15118073.
45. Huang Y-S, Yang J-J, Zhang X-C, Yang X-N, Huang Y-J, Xu C-R, Zhou Q, Wang Z, Su J, Wu Y. Impact of smoking status and pathologic type on epidermal growth factor receptor mutations in lung cancer. Chin Med J 2011, 124(16):2457-2460.
46. Kim HR, Ahn JR, Lee JG, Bang DH, Ha S-J, Hong YK, Kim SM, Nam KC, Rha SY, Soo RA. The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma. Yonsei Med J 2013, 54(4):865-874. 10.3349/ymj.2013.54.4.865, 3663229, 23709419.
47. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer biological and clinical implications. Cancer Res 2004, 64(24):8919-8923. 10.1158/0008-5472.CAN-04-2818, 15604253.
48. Liam C-K, Wahid MIA, Rajadurai P, Cheah Y-K, Ng TS-Y. Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinoma in Malaysian Patients. J Thorac Oncol 2013, 8(6):766-772. 10.1097/JTO.0b013e31828b5228, 23575413.
49. Sun P-L, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee C-T, Lee J-S, Chung J-H. High Incidence of EGFR Mutations in Korean Men Smokers with No Intratumoral Heterogeneity of Lung Adenocarcinomas: Correlation with Histologic Subtypes, EGFR/TTF-1 Expressions, and Clinical Features. J Thorac Oncol 2012, 7(2):323-330. 10.1097/JTO.0b013e3182381515, 22237264.
50. Uramoto H, So T, Nagata Y, Kuroda K, Shigematsu Y, Baba T, So T, Takenoyama M, Hanagiri T, Yasumoto K. Correlation between HLA alleles and EGFR mutation in Japanese patients with adenocarcinoma of the lung. J Thorac Oncol 2010, 5(8):1136-1142. 10.1097/JTO.0b013e3181e0b993, 20548248.
51. Hsu K-H, Chen K-C, Yang T-Y, Yeh Y-C, Chou T-Y, Chen H-Y, Tsai C-R, Chen C-Y, Hsu C-P, Hsia J-Y. Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns. J Thorac Oncol 2011, 6(6):1066-1072. 10.1097/JTO.0b013e31821667b0, 21512404.
52. Lee H-J, Kim YT, Kang CH, Zhao B, Tan Y, Schwartz LH, Persigehl T, Jeon YK, Chung DH. Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinomas: Relationship with CT Characteristics and Histologic Subtypes. Radiology 2013, 268(1):254-264. 10.1148/radiol.13112553, 23468578.